Compare INDP & SPHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INDP | SPHL |
|---|---|---|
| Founded | 2000 | 2002 |
| Country | United States | Singapore |
| Employees | N/A | 71 |
| Industry | Biotechnology: Pharmaceutical Preparations | Homebuilding |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.2M | 6.1M |
| IPO Year | 2021 | N/A |
| Metric | INDP | SPHL |
|---|---|---|
| Price | $2.41 | $2.70 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 67.1K | 9.5K |
| Earning Date | 05-11-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.27 | $0.35 |
| 52 Week High | $13.24 | $25.11 |
| Indicator | INDP | SPHL |
|---|---|---|
| Relative Strength Index (RSI) | 45.22 | 49.65 |
| Support Level | $2.36 | $2.46 |
| Resistance Level | $3.11 | $2.74 |
| Average True Range (ATR) | 0.41 | 0.19 |
| MACD | -0.07 | 0.03 |
| Stochastic Oscillator | 25.71 | 60.94 |
Indaptus Therapeutics Inc is a clinical biotechnology company that has developed a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. Its approach is based on the hypothesis that efficient activation of both innate and adaptive immune cells and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system activating signals that can be administered safely intravenously. Its patented technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria, designed to have reduced i.v. toxicity, but largely uncompromised ability to prime or activate many of the cellular components of innate and adaptive immunity. Its candidate, Decoy20 is for patients with solid tumors.
Springview Holdings Ltd is a company that conducts its operations through its indirect wholly-owned subsidiary which designs and constructs residential and commercial buildings in Singapore. It also provides four main types of works which includes new construction, reconstruction, Additions and Alterations (A&A), and other general contracting services such as renovation and design consultation. The company operates and manages its business as a single segment - in the development of construction projects. It derives maximum revenue from its Residential Customers.